EP1169038B9
(en)
|
1999-04-15 |
2013-07-10 |
Bristol-Myers Squibb Company |
Cyclic protein tyrosine kinase inhibitors
|
ES2257461T3
(es)
|
2000-12-21 |
2006-08-01 |
Bristol-Myers Squibb Company |
Inhibidores de tiazolilo de tirosina quinasas de la familia tec.
|
DK2311825T3
(en)
|
2000-12-21 |
2016-01-18 |
Novartis Ag |
Pyrimidinamines AS ANGIOGENESEMODULATORER
|
SI1347971T1
(sl)
*
|
2000-12-21 |
2006-06-30 |
Bristol Myers Squibb Co |
Tiazolilni inhibitorji tirozin kinaz Tec druzine
|
US20040102455A1
(en)
*
|
2001-01-30 |
2004-05-27 |
Burns Christopher John |
Method of inhibiting kinases
|
US7081454B2
(en)
|
2001-03-28 |
2006-07-25 |
Bristol-Myers Squibb Co. |
Tyrosine kinase inhibitors
|
EP1392300A1
(en)
|
2001-05-11 |
2004-03-03 |
Vertex Pharmaceuticals Incorporated |
2,5-disubstituted pyridine, pyrimidine, pyridazine and 1, 2, 4-triazine derivatives for use as p38 inhibitors
|
JP2005500294A
(ja)
|
2001-06-19 |
2005-01-06 |
ブリストル−マイヤーズ スクイブ カンパニー |
ホスホジエステラーゼ7に対するピリミジン阻害剤
|
CA2450562A1
(en)
*
|
2001-06-22 |
2003-01-03 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
DE10133665A1
(de)
*
|
2001-07-11 |
2003-01-30 |
Boehringer Ingelheim Pharma |
Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Herstellung
|
US7265134B2
(en)
|
2001-08-17 |
2007-09-04 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
JP2005511500A
(ja)
|
2001-08-31 |
2005-04-28 |
ザ ロックフェラー ユニバーシティー |
脳におけるホスホジエステラーゼ活性およびホスホジエステラーゼ1b媒介シグナル伝達の調節
|
WO2003027295A2
(en)
*
|
2001-09-24 |
2003-04-03 |
University Of Aarhus |
Methods for diagnosis and treatment of diseases associated with altered expression of jak1
|
WO2003062215A1
(en)
*
|
2002-01-25 |
2003-07-31 |
Kylix Pharmaceuticals B.V. |
4(hetero-) aryl substituted (thia-/oxa-/pyra) zoles for inhibition of tie-2
|
US20040014744A1
(en)
*
|
2002-04-05 |
2004-01-22 |
Fortuna Haviv |
Substituted pyridines having antiangiogenic activity
|
JP2005530745A
(ja)
|
2002-05-02 |
2005-10-13 |
メルク エンド カムパニー インコーポレーテッド |
チロシンキナーゼ阻害剤
|
CA2486183C
(en)
*
|
2002-05-23 |
2012-01-10 |
Cytopia Pty Ltd. |
Protein kinase inhibitors
|
US20040023978A1
(en)
*
|
2002-07-24 |
2004-02-05 |
Yu Ren |
Active salt forms with tyrosine kinase activity
|
US20040023981A1
(en)
*
|
2002-07-24 |
2004-02-05 |
Yu Ren |
Salt forms with tyrosine kinase activity
|
US6872724B2
(en)
|
2002-07-24 |
2005-03-29 |
Merck & Co., Inc. |
Polymorphs with tyrosine kinase activity
|
CA2504320A1
(en)
*
|
2002-10-30 |
2004-05-21 |
Vertex Pharmaceuticals Incorporated |
Compositions useful as inhibitors of rock and other protein kinases
|
AU2002953255A0
(en)
*
|
2002-12-11 |
2003-01-02 |
Cytopia Research Pty Ltd |
Protein kinase inhibitors
|
GB0305152D0
(en)
|
2003-03-06 |
2003-04-09 |
Novartis Ag |
Organic compounds
|
GB2400101A
(en)
*
|
2003-03-28 |
2004-10-06 |
Biofocus Discovery Ltd |
Compounds capable of binding to the active site of protein kinases
|
AR044519A1
(es)
*
|
2003-05-02 |
2005-09-14 |
Novartis Ag |
Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
|
EP1631279A4
(en)
*
|
2003-05-30 |
2007-03-14 |
Combinatorx Inc |
COMBINED THERAPY FOR THE TREATMENT OF NEOPLASMS
|
EP1644365A2
(en)
*
|
2003-07-02 |
2006-04-12 |
Biofocus Discovery Ltd |
Pyrazine and pyridine derivatives as rho kinase inhibitors
|
US7312215B2
(en)
|
2003-07-29 |
2007-12-25 |
Bristol-Myers Squibb Company |
Benzimidazole C-2 heterocycles as kinase inhibitors
|
US20050107350A1
(en)
*
|
2003-08-22 |
2005-05-19 |
Pharmacia Corporation |
Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith
|
GB0320197D0
(en)
|
2003-08-28 |
2003-10-01 |
Novartis Ag |
Organic compounds
|
US7572799B2
(en)
|
2003-11-24 |
2009-08-11 |
Pfizer Inc |
Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
|
ES2528302T3
(es)
|
2003-12-03 |
2015-02-06 |
Ym Biosciences Australia Pty Ltd |
Heterociclos con 6 anillos de nitrógeno fenilsustituidos como inhibidores de la polimerización de microtúbulos
|
US7294640B2
(en)
|
2004-02-06 |
2007-11-13 |
Merck & Co., Inc. |
Mitotic kinesin inhibitors
|
CN1956982A
(zh)
*
|
2004-05-21 |
2007-05-02 |
万有制药株式会社 |
具有氨基噻唑骨架的Cdk4、6选择性抑制剂
|
DE602005011279D1
(de)
*
|
2004-06-04 |
2009-01-08 |
Arena Pharm Inc |
Substituierte aryl- und heteroarylderivate als modulatoren des stoffwechsels und für die prophylaxe und behandlung von damit in zusammenhang stehenden erkrankungen
|
TW200621759A
(en)
*
|
2004-10-29 |
2006-07-01 |
Banyu Pharma Co Ltd |
Novel aminopyridine derivatives having aurora A selective inhibitory action
|
US7491720B2
(en)
|
2004-10-29 |
2009-02-17 |
Banyu Pharmaceutical Co., Ltd. |
Aminopyridine derivatives having Aurora A selective inhibitory action
|
WO2006051311A1
(en)
*
|
2004-11-12 |
2006-05-18 |
Galapagos Nv |
Nitrogen heteroaromatic compounds which bind to the active site of protein kinase enzymes
|
GB0428082D0
(en)
|
2004-12-22 |
2005-01-26 |
Welcome Trust The Ltd |
Therapeutic compounds
|
PT1846394E
(pt)
|
2005-02-04 |
2012-01-05 |
Astrazeneca Ab |
Derivados de pirazolilaminopiridina úteis como inibidores da quinase
|
AU2006215386B2
(en)
|
2005-02-16 |
2009-06-11 |
Astrazeneca Ab |
Chemical compounds
|
JP2008540622A
(ja)
|
2005-05-16 |
2008-11-20 |
アストラゼネカ アクチボラグ |
化合物
|
AU2006251161B2
(en)
|
2005-05-24 |
2011-06-30 |
Merck Serono Sa |
Thiazole derivatives and use thereof
|
WO2006129842A1
(ja)
*
|
2005-06-01 |
2006-12-07 |
Banyu Pharmaceutical Co., Ltd. |
オーロラa選択的阻害作用を有する新規アミノピリジン誘導体
|
CN101248050B
(zh)
|
2005-06-06 |
2013-07-17 |
武田药品工业株式会社 |
有机化合物
|
EP1893607A4
(en)
*
|
2005-06-09 |
2010-07-21 |
Merck Sharp & Dohme |
CHECKPOINT KINASE INHIBITORS
|
WO2007016228A2
(en)
*
|
2005-08-02 |
2007-02-08 |
Irm Llc |
5-substituted thiazol-2-yl amino compounds and compositions as protein kinase inhibitors
|
US20080194592A1
(en)
*
|
2005-08-23 |
2008-08-14 |
Intra-Cellular Therapies, Inc. |
Organic Compounds
|
DK1945631T3
(da)
|
2005-10-28 |
2012-10-22 |
Astrazeneca Ab |
4- (3-aminopyrazole) pyrimidinderivater til anvendelse som tyrosinkinaseinhibitorer til behandling af cancer
|
ES2372540T3
(es)
*
|
2005-11-01 |
2012-01-23 |
Array Biopharma, Inc. |
Activadores de glucocinasa.
|
US20070130203A1
(en)
*
|
2005-12-07 |
2007-06-07 |
Ask Jeeves, Inc. |
Method and system to provide targeted advertising with search results
|
KR100728221B1
(ko)
*
|
2005-12-08 |
2007-06-13 |
한국전자통신연구원 |
터보부호 ofdm 시스템용 반복적 잔류 주파수 위상 보정장치 및 그 방법
|
US7572809B2
(en)
*
|
2005-12-19 |
2009-08-11 |
Hoffmann-La Roche Inc. |
Isoquinoline aminopyrazole derivatives
|
CA2637172A1
(en)
*
|
2006-01-27 |
2007-08-09 |
Array Biopharma Inc. |
Pyridin-2-amine derivatives and their use as glucokinase activators
|
WO2007097839A2
(en)
*
|
2006-02-16 |
2007-08-30 |
Massachusetts Eye And Ear Infirmary |
Ansamycin analogs or heat shock 90 inhibitors in combination with pdt treatin conditions of the eye
|
AU2007235558B2
(en)
|
2006-03-24 |
2011-12-01 |
Array Biopharma Inc. |
2 -aminopyridine analogs as glucokinase activators
|
US7998978B2
(en)
|
2006-05-01 |
2011-08-16 |
Pfizer Inc. |
Substituted 2-amino-fused heterocyclic compounds
|
US8246966B2
(en)
*
|
2006-08-07 |
2012-08-21 |
University Of Georgia Research Foundation, Inc. |
Trypanosome microsome system and uses thereof
|
JP2008081492A
(ja)
*
|
2006-08-31 |
2008-04-10 |
Banyu Pharmaceut Co Ltd |
オーロラa選択的阻害作用を有する新規アミノピリジン誘導体
|
ES2411604T3
(es)
|
2006-11-13 |
2013-07-05 |
Intra-Cellular Therapies, Inc. |
Compuestos orgánicos
|
WO2008066755A2
(en)
*
|
2006-11-22 |
2008-06-05 |
University Of Georgia Research Foundation, Inc. |
Tyrosine kinase inhibitors as anti-kinetolastid and anti-apicomplexan agents
|
US9006258B2
(en)
|
2006-12-05 |
2015-04-14 |
Intra-Cellular Therapies, Inc. |
Method of treating female sexual dysfunction with a PDE1 inhibitor
|
CA2672903C
(en)
|
2006-12-20 |
2012-10-23 |
Amgen Inc. |
Heterocyclic compounds and their use in treating inflammation, angiogenesis and cancer
|
EP2366703B1
(en)
*
|
2007-02-13 |
2014-07-30 |
AB Science |
Polymorph form of 2-amino (nitroaryl) thiazole derivative
|
EP2133095A4
(en)
|
2007-03-05 |
2012-09-26 |
Kyowa Hakko Kirin Co Ltd |
PHARMACEUTICAL COMPOSITION
|
UA99459C2
(en)
|
2007-05-04 |
2012-08-27 |
Астразенека Аб |
9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
|
WO2009042435A1
(en)
|
2007-09-21 |
2009-04-02 |
Array Biopharma Inc. |
Pyridin-2 -yl-amino-i, 2, 4 -thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus
|
PL2195312T3
(pl)
|
2007-10-09 |
2013-04-30 |
Merck Patent Gmbh |
Pochodne pirydynowe użyteczne jako aktywatory glukokinazowe
|
BRPI0820722A2
(pt)
|
2007-12-20 |
2015-06-16 |
Novartis Ag |
Derivados de tiazol usados como inibidores de pi 3 cinases
|
WO2009130900A1
(ja)
*
|
2008-04-24 |
2009-10-29 |
日本曹達株式会社 |
オキシム誘導体、中間体化合物および植物病害防除剤
|
UA104147C2
(ru)
|
2008-09-10 |
2014-01-10 |
Новартис Аг |
Производная пирролидиндикарбоновой кислоты и ее применение в лечении пролиферативных заболеваний
|
JP2012518685A
(ja)
|
2009-02-25 |
2012-08-16 |
イントラ−セルラー・セラピーズ・インコーポレイテッド |
眼障害のためのpde1阻害剤
|
EP2434895A4
(en)
|
2009-05-13 |
2013-08-07 |
Intra Cellular Therapies Inc |
ORGANIC CONNECTIONS
|
US8293753B2
(en)
*
|
2009-07-02 |
2012-10-23 |
Novartis Ag |
Substituted 2-carboxamide cycloamino ureas
|
HUE033312T2
(en)
|
2009-07-20 |
2017-11-28 |
Bristol Myers Squibb Co |
Combination of anti CTLA4 antibody with etoposide for synergistic treatment of proliferative diseases
|
SG10201507362TA
(en)
|
2009-08-05 |
2015-10-29 |
Intra Cellular Therapies Inc |
Novel Regulatory Proteins And Inhibitors
|
JP5513620B2
(ja)
*
|
2009-08-31 |
2014-06-04 |
ポステック・アカデミー‐インダストリー・ファウンデーション |
血管内皮細胞成長因子受容体の阻害によるTh17炎症疾患治療方法およびこのための薬学的組成物
|
NZ599460A
(en)
|
2009-10-20 |
2014-07-25 |
Nestec Sa |
Proximity-mediated assays for detecting oncogenic fusion proteins
|
KR100953511B1
(ko)
*
|
2009-12-28 |
2010-04-21 |
(주)지노믹트리 |
건선 진단용 키트 및 칩
|
US9180127B2
(en)
|
2009-12-29 |
2015-11-10 |
Dana-Farber Cancer Institute, Inc. |
Type II Raf kinase inhibitors
|
WO2012060847A1
(en)
|
2010-11-07 |
2012-05-10 |
Targegen, Inc. |
Compositions and methods for treating myelofibrosis
|
US8623889B2
(en)
|
2010-12-17 |
2014-01-07 |
Genentech, Inc. |
Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof
|
JP2014508295A
(ja)
|
2011-02-17 |
2014-04-03 |
ネステク ソシエテ アノニム |
白血球及び腫瘍細胞を濾過により単離するための装置及び方法
|
UA112539C2
(uk)
|
2011-03-03 |
2016-09-26 |
Новартіс Аг |
Спосіб одержання похідних 2-карбоксамідциклоаміносечовини
|
US9255072B2
(en)
*
|
2011-03-04 |
2016-02-09 |
National Health Rsearch Institutes |
Pyrazole compounds and thiazole compounds as protein kinases inhibitors
|
RU2011122942A
(ru)
*
|
2011-06-08 |
2012-12-20 |
Общество С Ограниченной Ответственностью "Асинэкс Медхим" |
Новые ингибиторы киназ
|
RS53748B1
(en)
|
2011-09-12 |
2015-06-30 |
Sanofi |
2- (CHROMAN-6-ILOXY) -THIAZOLES AND THEIR USE AS PHARMACEUTICAL PRODUCTS
|
AU2011376746B2
(en)
|
2011-09-12 |
2017-06-15 |
Sanofi |
Substituted 2-(chroman-6-yloxy)-thiazoles and their use as pharmaceuticals
|
US8912224B2
(en)
|
2011-09-12 |
2014-12-16 |
Sanofi |
Substituted 2-(chroman-6-yloxy)-thiazoles and their use as pharmaceuticals
|
CN104284674A
(zh)
|
2012-05-04 |
2015-01-14 |
辉瑞公司 |
***相关抗原及基于疫苗的免疫治疗疗法
|
US9580413B2
(en)
|
2012-05-30 |
2017-02-28 |
Nippon Shinyaku Co., Ltd. |
Substituted pyrrolidines as ROS tyrosine kinase inhibitors
|
EP2956141A4
(en)
|
2013-02-17 |
2016-10-26 |
Intra Cellular Therapies Inc |
NEW USES
|
TWI659032B
(zh)
|
2013-03-15 |
2019-05-11 |
美商內胞醫療公司 |
有機化合物及其用途
|
US9545406B2
(en)
|
2013-03-15 |
2017-01-17 |
Intra-Cellular Therapies, Inc. |
Method of treating a CNS injury with a PDE1 inhibitor
|
CN103254184B
(zh)
*
|
2013-05-27 |
2015-03-18 |
湖南科技大学 |
5-取代-3-[5-羟基-4-吡喃酮-2-基-甲硫基]-4-氨基-1,2,4-***类化合物及其用途
|
CN103319467B
(zh)
*
|
2013-06-15 |
2015-10-14 |
湖南科技大学 |
一种4-[5-羟基-4-吡喃酮-2-基亚甲氨基]-3-巯基-1,2,4-***化合物及用途
|
MY190252A
(en)
|
2013-08-02 |
2022-04-08 |
Pfizer |
Anti-cxcr4 antibodies and antibody-drug conjugates
|
PL226024B1
(pl)
|
2013-10-23 |
2017-06-30 |
Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną |
Zastosowanie N-[2-[4-(4-metoksyfenylo)-1,3-tiazol-2-ilo]etylo]- -2-okso-2,5,6,7-tetrahydrocyklopenta[b] pirydyno-3-karboksyamidu
|
WO2015196186A1
(en)
|
2014-06-20 |
2015-12-23 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
US10285992B2
(en)
|
2014-08-07 |
2019-05-14 |
Intra-Cellular Therapies, Inc. |
Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
|
ES2745819T3
(es)
|
2014-08-07 |
2020-03-03 |
Intra Cellular Therapies Inc |
Derivados de imidazo[1,2-a]-pirazolo[4,3-e]-pirimidin-4-ona con actividad inhibidora de la PDE1
|
US10059702B2
(en)
*
|
2014-09-08 |
2018-08-28 |
The Johns Hopkins University |
Inhibitors of LC3/ATG3 interaction and their use in the treatment of cancer
|
ES2857567T3
(es)
|
2014-09-17 |
2021-09-29 |
Intra Cellular Therapies Inc |
Derivados de 7,8-dihidro-[2h]-imidazo-[1,2-a]pirazolo[4,3-e]pirimidin-4(5h)-ona como inhibidores de fosfodiesterasa 1 (PDE1) para tratar enfermedades, trastornos o lesiones del sistema nervioso central (SNC)
|
WO2016063122A1
(en)
|
2014-10-20 |
2016-04-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for screening a subject for a cancer
|
US10398774B2
(en)
|
2014-12-09 |
2019-09-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Human monoclonal antibodies against AXL
|
WO2016135041A1
(en)
|
2015-02-26 |
2016-09-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Fusion proteins and antibodies comprising thereof for promoting apoptosis
|
JP6861166B2
(ja)
|
2015-03-27 |
2021-04-21 |
ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド |
サイクリン依存性キナーゼの阻害剤
|
HUE050317T2
(hu)
|
2015-05-20 |
2020-11-30 |
Amgen Inc |
APJ receptor triazol agonistái
|
JP2018521021A
(ja)
*
|
2015-06-11 |
2018-08-02 |
バジリア・ファルマスーチカ・インターナショナル・アーゲーBasilea Pharmaceutica International Ag |
排出ポンプ阻害剤及びその治療的使用
|
US20180201687A1
(en)
|
2015-07-07 |
2018-07-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies having specificity to myosin 18a and uses thereof
|
WO2017032867A1
(en)
|
2015-08-27 |
2017-03-02 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the survival time of patients suffering from a lung cancer
|
CA2996978A1
(en)
|
2015-09-09 |
2017-03-16 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|
WO2017055324A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of cells of monocytic origin in a tissue sample
|
WO2017055322A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of neutrophils in a tissue sample
|
WO2017055327A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of endothelial cells in a tissue sample
|
WO2017055326A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of myeloid dendritic cells in a tissue sample
|
EP3419999B1
(en)
|
2016-02-26 |
2021-08-04 |
(INSERM) Institut National de la Santé et de la Recherche Médicale |
Antibodies having specificity for btla and uses thereof
|
JP2019510039A
(ja)
|
2016-03-28 |
2019-04-11 |
イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. |
新規組成物および方法
|
EP3452466B1
(en)
|
2016-05-03 |
2020-08-12 |
Amgen Inc. |
Heterocyclic triazole compounds as agonists of the apj receptor
|
AU2017270234B2
(en)
|
2016-05-25 |
2023-11-23 |
Assistance Publique-Hôpitaux De Paris (Aphp) |
Methods and compositions for treating cancers
|
WO2018011166A2
(en)
|
2016-07-12 |
2018-01-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of myeloid dendritic cells in a tissue sample
|
KR102487356B1
(ko)
|
2016-07-29 |
2023-01-12 |
엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔 |
종양 관련 대식세포를 표적화하는 항체 및 이의 용도
|
ES2906107T3
(es)
|
2016-09-12 |
2022-04-13 |
Intra Cellular Therapies Inc |
Usos novedosos
|
ES2883678T3
(es)
|
2016-10-21 |
2021-12-09 |
Inst Nat Sante Rech Med |
Métodos para promover la respuesta de linfocitos T
|
US20190345500A1
(en)
|
2016-11-14 |
2019-11-14 |
|Nserm (Institut National De La Santé Et De La Recherche Médicale) |
Methods and pharmaceutical compositions for modulating stem cells proliferation or differentiation
|
EP3541805B1
(en)
|
2016-11-16 |
2020-10-14 |
Amgen Inc. |
Heteroaryl-substituted triazoles as apj receptor agonists
|
WO2018093576A1
(en)
|
2016-11-16 |
2018-05-24 |
Amgen Inc. |
Alkyl substituted triazole compounds as agonists of the apj receptor
|
MA46827A
(fr)
|
2016-11-16 |
2019-09-25 |
Amgen Inc |
Composés de triazole à substitution cycloalkyle en tant qu'agonistes du récepteur apj
|
WO2018093579A1
(en)
|
2016-11-16 |
2018-05-24 |
Amgen Inc. |
Triazole phenyl compounds as agonists of the apj receptor
|
WO2018097944A1
(en)
|
2016-11-16 |
2018-05-31 |
Amgen Inc. |
Triazole furan compounds as agonists of the apj receptor
|
US10689367B2
(en)
|
2016-11-16 |
2020-06-23 |
Amgen Inc. |
Triazole pyridyl compounds as agonists of the APJ receptor
|
JP2020510432A
(ja)
|
2017-03-02 |
2020-04-09 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
Nectin−4への特異性を有する抗体及びその使用
|
WO2018185516A1
(en)
|
2017-04-05 |
2018-10-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy
|
WO2018189403A1
(en)
|
2017-04-14 |
2018-10-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of cancer
|
MX2019012476A
(es)
*
|
2017-04-21 |
2020-02-12 |
Hoffman Steven |
Composiciones y metodos para tratar la retinopatia.
|
EP3624798A1
(en)
|
2017-05-18 |
2020-03-25 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
Methods and pharmaceutical compositions for the treatment of mast cell diseases
|
WO2019072885A1
(en)
|
2017-10-11 |
2019-04-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
MAGNETIC NANOPARTICLES FOR THE TREATMENT OF CANCER
|
WO2019072888A1
(en)
|
2017-10-11 |
2019-04-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
METHODS OF PREDICTING THE THERAPEUTIC RESPONSE IN HEPATOCELLULAR CANCER
|
US11149040B2
(en)
|
2017-11-03 |
2021-10-19 |
Amgen Inc. |
Fused triazole agonists of the APJ receptor
|
JP7408036B2
(ja)
|
2017-11-24 |
2024-01-05 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
ガンを処置するための方法及び組成物
|
US11814686B2
(en)
|
2017-12-07 |
2023-11-14 |
Institut National de la Santéde la Recherche Médicale |
Method for screening and treating a subject for a cancer
|
CN107868040A
(zh)
*
|
2017-12-21 |
2018-04-03 |
苏州艾缇克药物化学有限公司 |
一种2‑氨基吡啶‑4‑甲酸甲酯的合成方法
|
JP7401442B2
(ja)
|
2018-01-31 |
2023-12-19 |
イントラ-セルラー・セラピーズ・インコーポレイテッド |
新規使用
|
WO2019185683A1
(en)
|
2018-03-28 |
2019-10-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating cancer
|
KR102245670B1
(ko)
*
|
2018-04-03 |
2021-04-29 |
영남대학교 산학협력단 |
신규한 6-헤테로아릴아미노-2,4,5-트라이메틸피리딘-3-올 화합물, 또는 이를 포함하는 염증성 장질환 및 자가면역 질환의 예방 또는 치료용 약학 조성물
|
JP2021521445A
(ja)
|
2018-04-13 |
2021-08-26 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
前立腺癌又は乳癌を患っている患者の転帰を予測するための及び処置のための方法
|
US11807624B2
(en)
|
2018-05-01 |
2023-11-07 |
Amgen Inc. |
Substituted pyrimidinones as agonists of the APJ receptor
|
WO2019211370A1
(en)
|
2018-05-03 |
2019-11-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating cancer
|
WO2019211369A1
(en)
|
2018-05-03 |
2019-11-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating cancer
|
WO2019229115A1
(en)
|
2018-05-30 |
2019-12-05 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating cancer
|
WO2019234221A1
(en)
|
2018-06-08 |
2019-12-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for stratification and treatment of a patient suffering from chronic lymphocytic leukemia
|
US20210236633A1
(en)
|
2018-08-06 |
2021-08-05 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating cancers
|
KR102328682B1
(ko)
*
|
2018-08-27 |
2021-11-18 |
주식회사 대웅제약 |
신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물
|
EP3849602A1
(en)
|
2018-09-10 |
2021-07-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Combination of her2/neu antibody with heme for treating cancer
|
US11066404B2
(en)
|
2018-10-11 |
2021-07-20 |
Incyte Corporation |
Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
|
WO2020165370A1
(en)
|
2019-02-13 |
2020-08-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for selecting a cancer treatment in a subject suffering from cancer
|
US11384083B2
(en)
|
2019-02-15 |
2022-07-12 |
Incyte Corporation |
Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
|
US11472791B2
(en)
|
2019-03-05 |
2022-10-18 |
Incyte Corporation |
Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
|
US20220136066A1
(en)
|
2019-03-06 |
2022-05-05 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method to diagnose a cmmrd
|
US11919904B2
(en)
|
2019-03-29 |
2024-03-05 |
Incyte Corporation |
Sulfonylamide compounds as CDK2 inhibitors
|
US11447494B2
(en)
|
2019-05-01 |
2022-09-20 |
Incyte Corporation |
Tricyclic amine compounds as CDK2 inhibitors
|
WO2020223469A1
(en)
|
2019-05-01 |
2020-11-05 |
Incyte Corporation |
N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
|
US20220251232A1
(en)
|
2019-05-20 |
2022-08-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Novel anti-cd25 antibodies
|
US20220290244A1
(en)
|
2019-08-02 |
2022-09-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for screening a subject for a cancer
|
JP2023509260A
(ja)
|
2019-08-14 |
2023-03-08 |
インサイト・コーポレイション |
Cdk2阻害剤としてのイミダゾリルピリミジニルアミン化合物
|
EP3800201A1
(en)
|
2019-10-01 |
2021-04-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Cd28h stimulation enhances nk cell killing activities
|
AR120184A1
(es)
|
2019-10-11 |
2022-02-02 |
Incyte Corp |
Aminas bicíclicas como inhibidoras de la cdk2
|
US20230040928A1
(en)
|
2019-12-09 |
2023-02-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies having specificity to her4 and uses thereof
|
WO2021228956A1
(en)
|
2020-05-12 |
2021-11-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method to treat cutaneous t-cell lymphomas and tfh derived lymphomas
|
WO2022101463A1
(en)
|
2020-11-16 |
2022-05-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of the last c-terminal residues m31/41 of zikv m ectodomain for triggering apoptotic cell death
|
KR20230165202A
(ko)
|
2021-01-29 |
2023-12-05 |
인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) |
Msi 암을 진단하는 방법
|
US20220389104A1
(en)
|
2021-05-28 |
2022-12-08 |
Ose Immunotherapeutics |
Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent
|
CN114230514A
(zh)
*
|
2021-11-26 |
2022-03-25 |
渭南瑞联制药有限责任公司 |
一种合成3-氟-2-氨基异烟腈的方法
|
US11976073B2
(en)
|
2021-12-10 |
2024-05-07 |
Incyte Corporation |
Bicyclic amines as CDK2 inhibitors
|
WO2024052503A1
(en)
|
2022-09-08 |
2024-03-14 |
Institut National de la Santé et de la Recherche Médicale |
Antibodies having specificity to ltbp2 and uses thereof
|
WO2024061930A1
(en)
|
2022-09-22 |
2024-03-28 |
Institut National de la Santé et de la Recherche Médicale |
New method to treat and diagnose peripheral t-cell lymphoma (ptcl)
|